Miguel Arce Rentería, PhD, Assistant Professor of Neuropsychology (in Neurology), speaks about factors that may contribute to an increased risk of developing dementia or Alzheimer's disease in Latinos
Caghan Kizil, PhD, MSc, Associate Professor of Neurological Sciences (in Neurology & in the Taub Institute) and colleagues discovered a mechanism that promotes neurogenesis in the zebrafish brain
Carol M. Troy, MD, PhD, Professor of Pathology & Cell Biology and Neurology at CUMC, discusses, based on a new study, how eye drops could be more effective in treating retinal vein occlusion
Dr. Lawrence S. Honig, Professor of Neurology at the CUIMC, comments on the significance of Food and Drug Administration approval of the Alzheimer’s disease drug, Lecanemab
Dr. Manly was elected to NAM for her pioneering work improving detection of cognitive impairment among racially, culturally, and socio-economically diverse adults
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people.
It is well established that people who had fewer opportunities to receive education when they were children are at higher risk for Alzheimer’s disease later in life, noted Dr. Jennifer Manly